Public Employees Retirement Association of Colorado reduced its stake in DexCom, Inc. (NASDAQ:DXCM – Free Report) by 5.1% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 55,298 shares of the medical device company’s stock after selling 2,974 shares during the quarter. Public Employees Retirement Association of Colorado’s holdings in DexCom were worth $7,670,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds also recently bought and sold shares of the stock. DSM Capital Partners LLC bought a new position in shares of DexCom in the fourth quarter worth about $28,000. Crewe Advisors LLC bought a new stake in DexCom during the 1st quarter worth approximately $29,000. Valley National Advisers Inc. lifted its holdings in DexCom by 73.0% during the fourth quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock valued at $30,000 after purchasing an additional 103 shares in the last quarter. Riverview Trust Co bought a new position in shares of DexCom in the first quarter worth approximately $32,000. Finally, MV Capital Management Inc. increased its stake in shares of DexCom by 99.3% in the fourth quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock worth $34,000 after purchasing an additional 138 shares in the last quarter. 97.75% of the stock is currently owned by hedge funds and other institutional investors.
DexCom Trading Up 5.4 %
Shares of NASDAQ DXCM opened at $67.48 on Tuesday. DexCom, Inc. has a 1-year low of $62.34 and a 1-year high of $142.00. The company has a debt-to-equity ratio of 1.00, a current ratio of 2.82 and a quick ratio of 2.48. The business’s 50 day moving average is $114.02 and its two-hundred day moving average is $123.33. The stock has a market capitalization of $27.04 billion, a P/E ratio of 43.54, a PEG ratio of 1.58 and a beta of 1.16.
Insider Buying and Selling at DexCom
In other news, EVP Michael Jon Brown sold 652 shares of the firm’s stock in a transaction dated Friday, May 31st. The shares were sold at an average price of $119.24, for a total value of $77,744.48. Following the completion of the sale, the executive vice president now owns 67,560 shares in the company, valued at approximately $8,055,854.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other news, EVP Sadie Stern sold 427 shares of the company’s stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $115.05, for a total transaction of $49,126.35. Following the transaction, the executive vice president now owns 75,877 shares of the company’s stock, valued at $8,729,648.85. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Michael Jon Brown sold 652 shares of the firm’s stock in a transaction that occurred on Friday, May 31st. The stock was sold at an average price of $119.24, for a total value of $77,744.48. Following the sale, the executive vice president now directly owns 67,560 shares of the company’s stock, valued at $8,055,854.40. The disclosure for this sale can be found here. Insiders have sold 3,483 shares of company stock worth $401,450 over the last quarter. Insiders own 0.30% of the company’s stock.
Analyst Ratings Changes
DXCM has been the subject of several recent analyst reports. Wells Fargo & Company dropped their target price on shares of DexCom from $145.00 to $80.00 and set an “overweight” rating for the company in a report on Friday. Royal Bank of Canada lowered their price objective on DexCom from $165.00 to $145.00 and set an “outperform” rating on the stock in a research report on Friday. Citigroup increased their target price on DexCom from $148.00 to $161.00 and gave the stock a “buy” rating in a research report on Wednesday, April 3rd. Stifel Nicolaus dropped their price target on DexCom from $132.00 to $90.00 and set a “buy” rating for the company in a research note on Friday. Finally, BTIG Research cut their price objective on shares of DexCom from $156.00 to $120.00 and set a “buy” rating for the company in a report on Friday. Seven equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $111.50.
View Our Latest Analysis on DexCom
DexCom Profile
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.
Featured Stories
- Five stocks we like better than DexCom
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Should You Invest in Bonds? Here’s What to Know
- What Does a Stock Split Mean?
- Why This Manufacturer is Committing to a Massive Buyback Program
- What is the FTSE 100 index?
- Top 2 Cheap Healthcare Stocks to Buy as Sector Outperforms
Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM – Free Report).
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.